Forane 99,9% w/w inhalācijas tvaiki, šķidrums Lettland - lettiska - Zāļu valsts aģentūra

forane 99,9% w/w inhalācijas tvaiki, šķidrums

abbvie ltd., united kingdom - izoflurāns - inhalācijas tvaiki, šķidrums - 99,9% w/w

Flutan 250 mg tabletes Lettland - lettiska - Zāļu valsts aģentūra

flutan 250 mg tabletes

medochemie ltd., cyprus - flutamīds - tablete - 250 mg

Pamecil 500 mg cietās kapsulas Lettland - lettiska - Zāļu valsts aģentūra

pamecil 500 mg cietās kapsulas

medochemie ltd., cyprus - ampicilīns - kapsula, cietā - 500 mg

Porphyrocin 250 mg apvalkotās tabletes Lettland - lettiska - Zāļu valsts aģentūra

porphyrocin 250 mg apvalkotās tabletes

medochemie ltd., cyprus - eritromicīns - apvalkotā tablete - 250 mg

Ramimed HCT 5 mg/25 mg tabletes Lettland - lettiska - Zāļu valsts aģentūra

ramimed hct 5 mg/25 mg tabletes

medochemie ltd., cyprus - ramiprilum, hydrochlorothiazidum - tablete - 5 mg/25 mg

Ramimed HCT 2,5 mg/12,5 mg tabletes Lettland - lettiska - Zāļu valsts aģentūra

ramimed hct 2,5 mg/12,5 mg tabletes

medochemie ltd., cyprus - ramiprilum, hydrochlorothiazidum - tablete - 2,5 mg/12,5 mg

Calcivid 600 mg/400 SV apvalkotās tabletes Lettland - lettiska - Zāļu valsts aģentūra

calcivid 600 mg/400 sv apvalkotās tabletes

beres pharmaceuticals ltd., hungary - kalcija, colecalciferolum - apvalkotā tablete - 600 mg/400 sv

Uniclophen 0,1% acu pilieni, šķīdums Lettland - lettiska - Zāļu valsts aģentūra

uniclophen 0,1% acu pilieni, šķīdums

unimed pharma ltd., slovakia - diklofenaka nātrija sāls - acu pilieni, šķīdums - 1 mg/ml

Calcium/Colecalciferol Beres 600 mg/800 SV apvalkotās tabletes Lettland - lettiska - Zāļu valsts aģentūra

calcium/colecalciferol beres 600 mg/800 sv apvalkotās tabletes

beres pharmaceuticals ltd., hungary - kalcija, colecalciferolum - apvalkotā tablete - 600 mg/800 sv

Oyavas Europeiska unionen - lettiska - EMA (European Medicines Agency)

oyavas

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiski līdzekļi - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. papildinformāciju par cilvēka epidermas augšanas faktora 2 receptora (her2) statusu, lūdzu, skatiet 5. sadaļā. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. sīkāku informāciju par her2 statusu, lūdzu, skatiet 5. sadaļā. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.